PortfoliosLab logo
10x Genomics, Inc. (TXG)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US88025U1097

CUSIP

88025U109

IPO Date

Sep 12, 2019

Highlights

Market Cap

$1.09B

EPS (TTM)

-$1.37

Total Revenue (TTM)

$624.66M

Gross Profit (TTM)

$429.69M

EBITDA (TTM)

-$127.01M

Year Range

$6.78 - $24.76

Target Price

$12.46

Short %

20.03%

Short Ratio

3.56

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

10x Genomics, Inc. (TXG) returned -33.64% year-to-date (YTD) and -57.47% over the past 12 months.


TXG

YTD

-33.64%

1M

15.24%

6M

-40.06%

1Y

-57.47%

3Y*

-42.90%

5Y*

-34.32%

10Y*

N/A

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of TXG, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20254.46%-28.73%-18.33%-5.27%15.24%-33.64%
2024-25.54%11.93%-19.53%-21.98%-23.43%-13.25%6.27%12.97%-3.30%-29.01%-0.81%-9.69%-74.34%
202328.51%1.47%17.40%-6.02%0.06%6.44%12.79%-17.67%-20.44%-14.47%23.36%28.58%53.57%
2022-35.37%-15.37%-6.63%-37.22%7.18%-11.60%-11.27%-17.83%-13.67%-4.56%42.24%-5.74%-75.54%
202120.87%4.00%1.69%9.28%-9.00%8.79%-6.43%-3.99%-17.25%10.78%-5.25%-2.52%5.20%
202019.86%-12.79%-21.81%28.16%-2.38%14.54%10.14%16.52%8.78%9.80%11.84%-7.52%85.70%
2019-4.45%15.08%11.88%17.51%44.55%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of TXG is 11, meaning it’s performing worse than 89% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of TXG is 1111
Overall Rank
The Sharpe Ratio Rank of TXG is 1111
Sharpe Ratio Rank
The Sortino Ratio Rank of TXG is 1212
Sortino Ratio Rank
The Omega Ratio Rank of TXG is 1313
Omega Ratio Rank
The Calmar Ratio Rank of TXG is 1313
Calmar Ratio Rank
The Martin Ratio Rank of TXG is 66
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

10x Genomics, Inc. Sharpe ratios as of May 31, 2025 (values are recalculated daily):

  • 1-Year: -0.76
  • 5-Year: -0.52
  • All Time: -0.39

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of 10x Genomics, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


10x Genomics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the 10x Genomics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the 10x Genomics, Inc. was 96.47%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current 10x Genomics, Inc. drawdown is 95.29%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-96.47%Apr 27, 2021993Apr 8, 2025
-51.63%Jan 29, 202038Mar 23, 2020104Aug 19, 2020142
-28.33%Feb 16, 202115Mar 8, 202120Apr 6, 202135
-25.69%Sep 19, 201910Oct 2, 201931Nov 14, 201941
-21.2%Oct 19, 202017Nov 10, 202041Jan 11, 202158
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of 10x Genomics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of 10x Genomics, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 64.9% positive surprise.


-4.00-3.00-2.00-1.000.0020212022202320242025
-0.10
-0.29
Actual
Estimate

Valuation

The Valuation section provides an overview of how 10x Genomics, Inc. is priced in the market compared to other companies in the Health Information Services industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for TXG relative to other companies in the Health Information Services industry. Currently, TXG has a P/S ratio of 1.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for TXG in comparison with other companies in the Health Information Services industry. Currently, TXG has a P/B value of 1.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items